SLC16A3 and neoplasm: The percentage of MCT4+EpCAM+, PD-L1+EpCAM+, and MCT4+PD-L1+EpCAM+ cells in tumor tissues was higher than 50% as shown in typical case 2 (Supplementary Material 2 and Figure S2), and EpCAM was used as a marker for poor prognosis of TNBC.